Devonian Health Group Inc (GSD) - Total Assets
Based on the latest financial reports, Devonian Health Group Inc (GSD) holds total assets worth CA$9.57 Million CAD (≈ $6.92 Million USD) as of January 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Devonian Health Group Inc cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Devonian Health Group Inc - Total Assets Trend (2015–2025)
This chart illustrates how Devonian Health Group Inc's total assets have evolved over time, based on quarterly financial data. Check earnings quality score of Devonian Health Group Inc to evaluate the quality of earnings relative to operating cash generation.
Devonian Health Group Inc - Asset Composition Analysis
Current Asset Composition (July 2025)
Devonian Health Group Inc's total assets of CA$9.57 Million consist of 55.1% current assets and 44.9% non-current assets.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 44.1% |
| Accounts Receivable | CA$475.88K | 3.0% |
| Inventory | CA$34.51K | 0.2% |
| Property, Plant & Equipment | CA$0.00 | 0.0% |
| Intangible Assets | CA$4.90 Million | 31.0% |
| Goodwill | CA$0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how Devonian Health Group Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Devonian Health Group Inc (GSD) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Devonian Health Group Inc's current assets represent 55.1% of total assets in 2025, an increase from 18.6% in 2015.
- Cash Position: Cash and equivalents constituted 44.1% of total assets in 2025, up from 8.6% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 30.0% of total assets, a decrease from 41.0% in 2015.
- Asset Diversification: The largest asset category is intangible assets at 31.0% of total assets.
Devonian Health Group Inc Competitors by Total Assets
Key competitors of Devonian Health Group Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Devonian Health Group Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.56 | 1.11 | 0.48 |
| Quick Ratio | 1.55 | 1.10 | 0.46 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$885.85K | CA$1.63 Million | CA$-891.55K |
Devonian Health Group Inc - Advanced Valuation Insights
This section examines the relationship between Devonian Health Group Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.93 |
| Latest Market Cap to Assets Ratio | 1.33 |
| Asset Growth Rate (YoY) | -48.5% |
| Total Assets | CA$15.83 Million |
| Market Capitalization | $21.12 Million USD |
Valuation Analysis
Above Book Valuation: The market values Devonian Health Group Inc's assets above their book value (1.33x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Devonian Health Group Inc's assets decreased by 48.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Devonian Health Group Inc (2015–2025)
The table below shows the annual total assets of Devonian Health Group Inc from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-07-31 | CA$15.83 Million ≈ $11.45 Million |
-48.49% |
| 2024-07-31 | CA$30.73 Million ≈ $22.23 Million |
+60.26% |
| 2023-07-31 | CA$19.18 Million ≈ $13.87 Million |
-11.16% |
| 2022-07-31 | CA$21.59 Million ≈ $15.62 Million |
+47.77% |
| 2021-07-31 | CA$14.61 Million ≈ $10.57 Million |
-12.51% |
| 2020-07-31 | CA$16.70 Million ≈ $12.08 Million |
-2.63% |
| 2019-07-31 | CA$17.15 Million ≈ $12.40 Million |
-10.49% |
| 2018-07-31 | CA$19.16 Million ≈ $13.86 Million |
+65.75% |
| 2017-07-31 | CA$11.56 Million ≈ $8.36 Million |
+14.73% |
| 2016-07-31 | CA$10.07 Million ≈ $7.29 Million |
+11410.58% |
| 2016-06-30 | CA$87.52K ≈ $63.31K |
-99.25% |
| 2015-07-31 | CA$11.73 Million ≈ $8.49 Million |
-- |
About Devonian Health Group Inc
Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for Atopic dermatitis in pediatric population; in phase 2 clinical trial for HFS associated to chemotherapy; and in phase 2/3 clinical trial for Radiodermatitis as… Read more